S pecific bacterial biofilm is well established as the etiologic agent of periodontal diseases; 1 however, evidence suggests that the severity and progression of periodontal destruction may be related to some environmental and systemic modifiers, such as smoking and diabetes mellitus (DM). 2, 3 DM is a metabolic disease characterized by abnormal glucose tolerance and hyperglycemia that can be involved in several oral and systemic long-term complications. [4] [5] Type 2 DM is the most prevalent type of DM among middle-aged subjects; it results from changes in insulin molecules and/or their cell receptors, impairing insulin function. 5 A number of studies 2,3,6-10 reported high prevalence, severity, and progression of periodontal diseases in subjects with diabetes, providing substantial evidence to support DM as a risk factor for periodontal diseases. It was also suggested that DM and periodontitis may have a mutual influence because at the same time that DM predisposes to periodontal diseases, the established periodontitis may intensify the DM. 11, 12 The chronic challenge of the periodontal pathogens may provide a constant source of proinflammatory cytokines that may be associated with tissue insulin resistance and poor glycemic control in subjects with diabetes. 13, 14 Based on this theory, it was hypothesized that the successful control of periodontal infection could improve the clinical signs of periodontitis as well as the metabolic control of DM. 13 Various investigations [15] [16] [17] [18] [19] [20] demonstrated that scaling and root planing (SRP), associated or not with antibiotics, yielded clinical benefits in subjects with diabetes, including a reduction in probing depth (PD), bleeding on probing (BOP), and suppuration (SUP) and a gain in clinical attachment level (CAL). Simultaneously, these interventional studies [15] [16] [17] [18] [19] [20] [21] [22] [23] assessed the potential effects of different types of periodontal therapy on glycemic control in subjects with diabetes, as measured by glycosylated hemoglobin (HbA1c) levels. Some investigations 13, 15, 21, 22 suggested that improvements in periodontal condition positively affect metabolic control, whereas other studies 16, 20, 23, 24 did not find this beneficial effect.
It was hypothesized that partial-mouth SRP (PMSRP) would lead to reinfection of the already instrumented sites from sites not yet treated and/or other intraoral niches, whereas the short-term fullmouth elimination of pathogens would help to prevent such reinfection. 25, 26 Particularly in a group susceptible to infection, e.g., subjects with diabetes, fullmouth SRP (FMSRP) could present some advantages over PMSRP, such as a decrease in the number of visits to the dentist and an abrupt reduction in bacterial infection. Despite evidence of the effect of FMSRP in subjects with diabetes, 16, 19, 27 to the best of our knowledge, no study has evaluated the long-term clinical and glycemic impact of FMSRP compared to PMSRP in subjects with type 2 diabetes.
Cross-sectional studies [28] [29] [30] [31] observed that subjects with poor glycemic control had more severe periodontitis than individuals with well-controlled disease. Although many studies [15] [16] [17] [18] [19] [20] [21] [22] [23] evaluated the effect of various periodontal treatments for subjects with diabetes, they focused on the clinical and metabolic responses to these therapies, considering the diabetic group as a whole. Few interventional studies 32, 33 differentiated the glycemic status of the subjects with diabetes to assess the effect of periodontal therapy in individuals with better-and poorly controlled disease.
Therefore, the aims of the present study were to evaluate the clinical and metabolic effects of FMSRP in subjects with type 2 diabetes and chronic periodontitis compared to PMSRP at 3 and 6 months follow-up and to assess the impact of the glycemic status on the clinical and metabolic response to non-surgical periodontal therapy.
MATERIALS AND METHODS

Sample Size Calculation
The ideal sample size to ensure adequate power for this clinical trial was calculated considering differences ‡1 mm for CAL and a standard deviation of 0.94 mm between groups in initially deep periodontal pockets (>6 mm). Based on these calculations, it was decided that 14 subjects per group were necessary to provide 80% power with a = 0.05.
Subject Population
Thirty-six subjects (age range: 36 to 70 years) diagnosed with type 2 DM and chronic periodontitis were selected from the population referred to the Periodontal Clinic of Guarulhos University, from July 2007 until January 2008. Detailed medical and dental records were obtained. Subjects who fulfilled the inclusion/exclusion criteria were invited to participate in the study. All eligible subjects were thoroughly informed of the nature, potential risks, and benefits of the study and provided written informed consent. The study protocol was approved by Guarulhos University's Ethics Committee in Clinical Research.
Inclusion and Exclusion Criteria
Data on the duration of DM and medications were retrieved from the medical records of the subjects at the beginning of the study. All subjects had received a diagnosis of type 2 DM within the past 5 years and were under insulin supplementation, a diet regimen, and/or oral hypoglycemic agents. Subjects were diagnosed with generalized chronic periodontitis, based on the clinical and radiographic criteria proposed by the 1999 World Workshop for Classification of Periodontal Diseases and Conditions. 34 All subjects were >30 years old; had ‡15 teeth, excluding third molars and teeth with severe periodontitis and/or caries, indicated to surgical extraction; and >30% of sites with PD and CAL ‡5 mm at baseline.
Exclusion criteria were pregnancy, lactation, current smoking or smoking within the past 5 years, periodontal and/or antibiotic therapies in the previous 6 months, use of mouthrinses containing antimicrobials in the preceding 2 months, any systemic condition (except DM) that could affect the progression of periodontal disease (e.g., immunologic disorders), and the long-term administration of anti-inflammatory and immunosuppressive medications. Subjects with periapical pathology, orthodontic appliances, and multiple systemic complications of DM were also excluded from the study.
Fasting Plasma Glucose (FPG) and Glycosylated Hemoglobin Levels All blood analyses were performed by a single laboratory (Guarulhos University Clinical Analysis Laboratory). Blood samples were taken from each subject at baseline and at 3 and 6 months post-therapy. FPG, measured using the glucose oxidase method, was expressed in milligrams per deciliter (normal healthy range, 60 to 110 mg/dl). HbA1c, measured by high-pressure liquid chromatography, was expressed as a percentage (normal healthy range, 4.5% to 8%). Baseline HbA1c values ‡9% were considered poorly controlled DM, and baseline HbA1c levels <9% were considered better-controlled DM. 35 
Clinical Monitoring
All clinical examinations were performed by one examiner (VRS), calibrated according to the method described by Araujo et al. 36 The intraexaminer variability was 0.21 mm for PD and 0.25 mm for CAL. The examiner was able to provide repeatable PD and CAL measurements of under 0.5 mm of differences. The clinical parameters registered dichotomously, i.e., BOP and SUP, were evaluated by the Kappa-Light test, and the intraexaminer agreement was >0.85. The examiner was unaware of the treatment assignment and the metabolic status of the subjects.
The following parameters were assessed at six sites of all teeth, excluding third molars (mesio-buccal, medio-buccal, disto-buccal, mesio-lingual, mediolingual, and disto-lingual) using a manual periodontal probe (15 mm): † visible plaque accumulation (plaque index; PI): presence or absence of plaque along the cervical margin; 37 BOP: presence or absence of bleeding up to 15 seconds after gentle probing; SUP: presence or absence of spontaneous SUP or SUP on probing; PD: distance between the gingival margin and the bottom of the sulcus/pocket; and CAL: distance between the cemento-enamel junction and the bottom of the sulcus/pocket. Clinical examinations were performed at baseline and at 3 and 6 months post-therapy.
Experimental Design and Treatment Protocols
All subjects were submitted to the hygiene phase of periodontal therapy, including supragingival plaque and calculus removal, exodontia, provisional restoration, and removal of overhangs of fillings. They were instructed to perform a brushing technique using a soft toothbrush, dental floss, and interdental toothbrushes, as necessary. Moreover, all volunteers received the same brand of toothpaste to use during the course of the study. ‡ In this prospective, parallel, masked, randomized, and controlled clinical trial, 36 subjects with type 2 diabetes and chronic periodontitis were randomly assigned, by the toss of a coin by the same assessor (PMD), to the control or test group. FMSRP (test group; n = 18): SRP was completed in two appointments, lasting ;120 minutes each, performed under local anesthesia (3% prilocaine with felypressin) using periodontal curets § and an ultrasonic device. i SRP of all teeth was concluded in a maximum of 24 hours on two consecutive days, starting with the right maxillary and mandibular quadrants.
PMSRP (control; n = 18): SRP was completed in four appointments, lasting ;60 minutes each, performed under local anesthesia (3% prilocaine with felypressin) using periodontal curets ¶ and an ultrasonic device. # Treatment of all teeth was concluded in a maximum of 21 days, starting in the right maxillary quadrant, followed by the right mandibular, left maxillary, and left mandibular quadrants.
SRP in both groups was performed by the same operator without the use of any antibiotics or local antimicrobials. The supportive therapy, including professional plaque control with an abrasive sodium carbonate air-powder system** and reinstruction of oral hygiene, was performed at 3 and 6 months post-therapy. The subjects were asked to report any changes in their DM treatment regimen at the follow-up appointments. To assess the effects of the periodontal treatments on metabolic control, no changes in the medication or diet were made during the study period (6 months).
Statistical Analysis
The statistical analysis was performed using a commercially available software program. † † The biostatistician was unaware of the treatment assignment or the metabolic status of the subjects. Data were examined first for normality using the Kolmogorov-Smirnov test; because they did not achieve normality, analysis was performed using non-parametric methods. The primary variables were the changes in PD and CAL levels from baseline to 3 and 6 months. The secondary variables were the changes in the other clinical parameters and in the levels of HbA1c and FPG. The percentage of sites with visible plaque, BOP, and SUP and mean PD, CAL, HbA1c, and FPG levels were computed for each subject. Clinical parameters were averaged across subjects and in the therapeutic (PMSRP and FMSRP) and glycemic (better or poorly controlled DM) groups. HbA1c and FPG data were also averaged in the therapeutic and glycemic groups. The changes in PD and CAL over time were examined in subsets of sites for both therapeutic groups, according to the initial PD: £3 mm (shallow), 4 to 6 mm (intermediate), and ‡7 mm (deep). Values for each clinical parameter were averaged separately within the three PD categories in each subject and then averaged across subjects in the treatment groups. The significance of the clinical and metabolic differences between FMSRP and PMSRP, as well as between subjects with better-and poorly controlled disease, was compared using the Mann-Whitney U test. The significance of differences in age and duration of DM between FMSRP and PMSRP groups was also compared using the Mann-Whitney U test. The Friedman test was used to detect statistically significant differences within each therapeutic or glycemic group among the three time points. When there were significant differences by the Friedman test, a pairwise comparison was performed using the Wilcoxon test. The x 2 test was used to detect differences in the frequencies of gender between FMSRP and PMSRP groups. The level of significance was set at 5%.
RESULTS
Subject Retention
No subject dropped out of the study. Thus, 36 subjects completed the study: 18 in the control group (PMSRP) and 18 in the test group (FMSRP). No subject reported any adverse effects, such as fever or indisposition, during the study.
Clinical Results
The demographic characteristics of the subjects at baseline for both therapeutic groups are presented in Table 1 . No statically significant differences were observed between PMSRP and FMSRP groups with regard to age, duration of DM, gender, glycemic control, and distribution of DM treatment regimens. Table 2 presents the mean full-mouth values for the clinical parameters at baseline and at 3 and 6 months after therapy. No statistically significant differences were observed between therapeutic groups for any clinical parameters at any time point (P >0.05). Both therapies led to a statistically significant decrease in the mean percentage of sites with visible plaque and BOP and the mean PD and CAL at 3 months (P <0.05). In addition, these improvements were sustained at 6 months post-therapy (P <0.05). SUP progressively decreased in the FMSRP group over time (P <0.05). However, the percentage of sites exhibiting SUP significantly decreased in the PMSRP group only at 6 months (P <0.05).
The mean changes in PD and CAL for both treatment groups between baseline and 3 months and between baseline and 6 months post-therapy are presented in Figure 1 . The results are organized according to full-mouth values as well as different baseline PD categories: shallow (£3 mm), intermediate (4 to 6 mm), and deep ( ‡7 mm) sites. FMSRP and PMSRP groups showed similar reductions in PD and CAL, considering full-mouth values and all PD categories at 3 and 6 months post-therapy. For both groups, the initially deep sites had the greatest reduction in mean PD and CAL, followed by the intermediate and shallow sites.
HbA1c ranged from 4.8% to 8.7% and from 9% to 12% for the subjects with better-and poorly controlled disease, respectively. The comparisons between better and poor control were made considering the non-surgical periodontal therapy as a whole (FMSRP plus PMSRP). Statistical comparisons among four groups (poorly controlled disease treated by FMSRP, better-controlled disease treated by FMSRP, poorly controlled disease treated by PMSRP, and better-controlled disease treated by PMSRP) were not possible because of the small sample size per group, as observed in Table 1 . The clinical parameters of subjects with better-(HbA1c level <9%) and poorly controlled (HbA1c level ‡9%) disease at baseline and at 3 and 6 months posttherapy are presented in Table 3 . A statistically significant decrease in the mean percentage of sites with visible plaque, BOP, and SUP and in mean PD and CAL was observed for subjects with poor and good metabolic control at 3 and 6 months post-therapy (P <0.05). Although not statistically significant, subjects with diabetes with poor metabolic control had a tendency for higher visible plaque accumulation (82.9% -22.6%) than those with good metabolic control (56.9% -34.5%) at baseline (P >0.05). The mean percentage of sites with BOP and SUP and the mean PD and CAL were similar for subjects with better-and poorly controlled disease at baseline (P >0.05). There There are no differences between groups at baseline regarding age and duration of DM (Mann-Whitney test) and regarding gender, glycemic control, and DM treatment regimen (x 2 test; P >0.05).
were no differences with regard to any clinical parameter between these two groups at 3 months after periodontal treatment (P >0.05). However, subjects with better-controlled disease had a lower mean CAL (3.1 -0.7 mm versus 3.5 -0.8 mm) at 6 months after SRP (P <0.05).
Metabolic Results
There were no statistically significant differences between FMSRP and PMSRP groups in the mean HbA1c and FPG levels at baseline and at 3 and 6 months post-therapy (P >0.05). In addition, there were no changes in the HbA1c values from baseline to 3 months and to 6 months for any therapeutic group (P >0.05). A statistically significant increase in mean FPG level was observed for the FMSRP group at 3 and 6 months and for the PMSRP group at 6 months after therapy ( Table 2 ). The distribution of subjects stratified by changes in HbA1c from baseline to 3 and 6 months are presented in Table 4 . A ‡0.5% increase or decrease from baseline to the follow-up examination was considered a change; otherwise, the level of glycemic control was considered stable. As expected, the mean level of HbA1c was higher for subjects with poorly controlled disease at baseline. This difference was also observed at 6 months after therapy but not at 3 months after therapy. There were no changes in HbA1c over time for subjects with poorly controlled disease. Unexpectedly, the mean levels of HbA1c increased from baseline to 3 months post-therapy for the individuals with better-controlled disease (7.3% -1.2% to 9.1% -1.8%). FPG levels were higher for subjects with poor glycemic control than for those with good control at all experimental times. There was an increase in the FPG levels in the group with poorly controlled disease at 3 and 6 months after treatment, whereas these values remained unchanged for the group with better-controlled disease (Table 3) .
DISCUSSION
There is increasing interest in the development of efficient periodontal therapies for subjects with diabetes, a group considered at risk for periodontal diseases. In addition, various studies [15] [16] [17] [18] [19] [20] [21] 23 aimed to elucidate the effects of periodontal therapy on the glycemic control of subjects with diabetes. The present study evaluated the clinical and metabolic effects of FMSRP compared to PMSRP in subjects with type 2 diabetes and chronic periodontitis. In addition, the impact of non-surgical SRP on clinical and metabolic Different letters indicate statistically significant differences over time by the Friedman and Wilcoxon tests (P <0.05). There were no differences between the treatment groups at any time point; Mann-Whitney test (P >0.05).
Figure 1.
Mean -SD changes in PD and CAL for the full mouth and at sites with initial PD £3, 4 to 6, and ‡7 mm between baseline and 3 and 6 months for FMSRP and PMSRP groups. There were no differences between the treatment groups at any time point. Mann-Whitney test; P >0.05.
parameters was observed in subjects with better-and poorly controlled disease. In this study, SRP in 24 hours was not superior to quadrant-wise SRP performed over a 3-week interval in subjects with diabetes. Thus, both FMSRP and PMSRP may be considered effective in the treatment of subjects with diabetes and chronic periodontitis, producing reductions in PD and BOP and gain in CAL. Our results from subjects with diabetes are in agreement with previous studies 26, 38 and systematic reviews, 39, 40 which demonstrated that an improvement in clinical parameters in subjects with chronic periodontitis and without diabetes could be achieved equally by FMSRP and PMSRP after 6 months.
SRP alone or in association with antimicrobials yielded improvements in the periodontal condition of subjects with diabetes and periodontitis. [15] [16] [17] [18] [19] [20] 22 The favorable clinical response observed for the PMSRP group in our study corroborates the findings of previous investigations 17, 18, 20, 22 evaluating this conventional therapy. Also, our results for the FMSRP group are consistent with studies 15, 19 that focused on the reduction of periodontal infection in a short-term interval and found improvements in the periodontal status of subjects with diabetes.
Cross-sectional studies [28] [29] [30] [31] 41 demonstrated that subjects with poorly controlled disease have more severe periodontitis than subjects with well-controlled diabetes. Tsai et al. 30 noted that subjects with poorly controlled (HbA1c levels >9%) type 2 diabetes had a higher prevalence of severe periodontal disease than individuals without diabetes. Lim et al. 31 demonstrated that subjects with type 1 or 2 diabetes with HbA1c levels <8% exhibited a better periodontal condition than individuals with HbA1c levels ‡8%. However, the existing interventional investigations evaluated the effects of different therapies for diabetic groups as a whole, without considering their glycemic status. Therefore, to provide information about the impact of glycemic control on the clinical and metabolic response to SRP, we divided the subjects with type 2 diabetes into those with better-controlled disease (HbA1c <9%) or poorly controlled disease (HbA1c ‡9%).
Although not statistically significant, there was a trend toward more plaque accumulation in the subjects with poorly controlled disease at baseline ( Table  3 ). The compliance of subjects with diabetes with oral hygiene was already associated with HbA1c levels, with improved compliance among those with better glycemic control. 24, 42 When FMSRP and PMSRP were evaluated together, the response to periodontal treatment was similar for subjects with better-and poorly controlled disease for almost all clinical parameters (Table 3) ; only the mean CAL was lower for the subjects with better-controlled disease at 6 months. A ‡0.5% increase or decrease from baseline to the follow-up examination was considered a change; otherwise, the level of glycemic control was considered stable.
Christgau et al. 32 did not find a significant influence of metabolic control on the periodontal response in subjects with diabetes stratified according to different levels of HbA1c. However, the investigators included type 1 and 2 DM, and their sample of subjects with poor glycemic control was too small (only three individuals). Tervonen and Karjalainen 33 observed a worse clinical response to periodontal therapy in subjects with type 1 diabetes with poor metabolic control, identified by medical history, compared to subjects with well-controlled disease. However, the methodologic differences of these studies hampered a more straight comparison to our results. Based on the theory that infections are implicated in tissue insulin resistance, 43, 44 it was hypothesized that DM and periodontitis could have reciprocal influence. 12, 13 Consequently, the effective reduction of pathogens after periodontal therapy could promote a better metabolic control. HbA1c, which estimates the stable glucose/hemoglobin binding over the prior 3 months, is considered an accurate means of following glycemic control in a subject already diagnosed with DM. In our study, the levels of HbA1c did not change significantly at 3 and 6 months following FMSRP or PMSRP (Table 2 ). These findings are in agreement with studies 16, 20, [23] [24] [25] in which PMSRP and FMSRP resulted in improvements in the clinical parameters without significant changes in the glycemic control in individuals with diabetes. Conversely, our results are in contrast with those from investigations 15, 17, 19, 21, 22 that showed improvements in glycemic control in individuals with type 2 DM after PMSRP or FMSRP. The contribution of periodontal therapy to improving glycemic control in subjects with type 2 diabetes remains controversial; caution should be used in the interpretation of these findings because of differences in study designs, types of DM, initial levels of HbA1c, therapeutic protocols, severity of periodontitis, and sample sizes. It was established that a large sample size ( ‡246 subjects) is needed for any significant reduction in HbA1c to be observed. 23 Surprisingly, many subjects had an increase in HbA1c levels after therapy (Table 4) , and the increase was statistically significant for subjects with bettercontrolled disease at 3 months after SRP (Table 3) . Therefore, we noted that many subjects with diabetes are able to maintain intermittent control of glycemia. Tervonen et al. 45 also observed that some subjects with better-or poorly controlled type 1 diabetes had improvements in DM control after periodontal therapy, whereas the glycemic control remained stable or increased in other subjects. These findings may be attributed to the role of other variables, such as diet, physical activity, compliance with medications, other infectious diseases, and medical monitoring, on the glycemic status. This hypothesis can be reinforced by the observation of changes in the levels of FPG, which reflect the glycemic control at a given time point and may vary rapidly according to diet, physical activity, and medications. In this way, the influence of diabetic status on the periodontal healing response probably becomes more significant when the metabolic control of DM is constantly poor or good. Therefore, the maintenance of lower CAL observed for subjects with better-controlled disease at 6 months and the appearance of further clinical differences between subjects with poorly and better-controlled disease might be dependent on the long-term metabolic control in these subjects.
CONCLUSIONS
PMSRP and FMSRP resulted in comparable improvements in periodontal parameters in subjects with type 2 diabetes and chronic periodontitis at 3 and 6 months. In addition, neither therapy resulted in improvements in the HbA1c level at 3 and 6 months. Finally, subjects with better-and poorly controlled diabetes showed similar clinical responses to SRP, with only a significantly lower CAL for subjects with better-controlled disease at 6 months. Longitudinal follow-up is needed to evaluate the long-term outcomes in relation to periodontal health and the systemic implications for these subjects.
